Phosplatin Therapeutics receives US FDA Orphan Drug designation for the use of PT-112 in patients with Thymoma and Thymic Carcinoma Press Release Oct 25 Written by Guest User View designation on FDA.gov Guest User Previous Previous Phosplatin Therapeutics Convenes Clinical Advisory Board with Prostate Cancer Experts During ESMO 2019 Annual Congress Next Next Phosplatin honored at the European Society of Medical Oncology (ESMO) 2018 Annual Meeting
Phosplatin Therapeutics receives US FDA Orphan Drug designation for the use of PT-112 in patients with Thymoma and Thymic Carcinoma Press Release Oct 25 Written by Guest User View designation on FDA.gov Guest User
